Table of Contents
International Journal of Molecular Imaging
Volume 2011 (2011), Article ID 372509, 11 pages
http://dx.doi.org/10.1155/2011/372509
Review Article

The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II

1Department of Neuroscience, Neurology, University Hospital, Uppsala University, 751 85 Uppsala, Sweden
2Department of Radiation-Oncology (MAASTRO), GROW (School for Oncology and Developmental Biology), Maastricht University Medical Centre (MUMC), 6202 Maastricht, The Netherlands

Received 21 October 2010; Revised 15 January 2011; Accepted 25 January 2011

Academic Editor: Ronald L. Van Heertum

Copyright © 2011 Anja Smits and Brigitta G. Baumert. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Duffau and L. Capelle, “Preferential brain locations of low-grade gliomas: comparison with glioblastomas and review of hypothesis,” Cancer, vol. 100, no. 12, pp. 2622–2626, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Leighton, B. J. Fisher, G. Bauman et al., “Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation,” Journal of Clinical Oncology, vol. 15, no. 4, pp. 1294–1301, 1997. View at Google Scholar · View at Scopus
  4. J. O. Bampou, G. Bauman, and J. G. Cairncross, “Adult low-grade gliomas: natural history, prognostic factors and timing of treatment,” in The Practical Management of Low-Grade Gliomas, J. P. Rock, M. L. Rosenblum, E. G. Shaw, and J. G. Cairncross, Eds., pp. 135–148, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 1999. View at Google Scholar
  5. E. G. Shaw, B. W. Scheithauer, and J. R. O'Fallen, “Supratentorial gliomas: a comparative study by grade and histologic type,” Journal of Neuro-Oncology, vol. 31, no. 3, pp. 273–278, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. P. H. Wessels, W. E. J. Weber, G. Raven, F. C. S. Ramaekers, A. H. N. Hopman, and A. Twijnstra, “Supratentorial grade II astrocytoma: biological features and clinical course,” Lancet Neurology, vol. 2, no. 7, pp. 395–403, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. G. E. Keles, K. R. Lamborn, and M. S. Berger, “Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome,” Journal of Neurosurgery, vol. 95, no. 5, pp. 735–745, 2001. View at Google Scholar · View at Scopus
  8. R. Soffietti, B. G. Baumert, L. Bello et al., “Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force,” European Journal of Neurology, vol. 17, no. 9, pp. 1124–1133, 2010. View at Publisher · View at Google Scholar
  9. J. S. Smith, E. F. Chang, K. R. Lamborn et al., “Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas,” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1338–1345, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Pouratian and D. Schiff, “Management of Low-Grade Glioma,” Current Neurology and Neuroscience Reports, vol. 10, no. 3, pp. 224–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. B. G. Baumert and R. Stupp, “Is there a place for radiotherapy in low-grade gliomas?” Advances and Technical Standards in Neurosurgery, vol. 35, pp. 159–182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. B. M. F. Karim, B. Maat, R. Hatlevoll et al., “A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European organization for research and treatment of cancer (EORTC) study 22844,” International Journal of Radiation Oncology Biology Physics, vol. 36, no. 3, pp. 549–556, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Shaw, R. Arusell, B. Scheithauer et al., “Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study,” Journal of Clinical Oncology, vol. 20, no. 9, pp. 2267–2276, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. G. M. Kiebert, D. Curran, N. K. Aaronson et al., “Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844),” European Journal of Cancer, vol. 34, no. 12, pp. 1902–1909, 1998. View at Publisher · View at Google Scholar
  15. M. J. Van Den Bent, D. Afra, O. De Witte et al., “Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial,” Lancet, vol. 366, no. 9490, pp. 985–990, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. J. C. Buckner, D. Gesme, J. R. O'Fallon et al., “Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities,” Journal of Clinical Oncology, vol. 21, no. 2, pp. 251–255, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Kaloshi, A. Benouaich-Amiel, F. Diakite et al., “Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome,” Neurology, vol. 68, no. 21, pp. 1831–1836, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Quinn, D. A. Reardon, A. H. Friedman et al., “Phase II trial of temozolomide in patients with progressive low-grade glioma,” Journal of Clinical Oncology, vol. 21, no. 4, pp. 646–651, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Pace, A. Vidiri, E. Galiè et al., “Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response,” Annals of Oncology, vol. 14, no. 12, pp. 1722–1726, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Reifenberger and D. N. Louis, “Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology,” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 2, pp. 111–126, 2003. View at Google Scholar · View at Scopus
  21. F. Pignatti, M. Van den Bent, D. Curran et al., “Prognostic factors for survival in adult patients with cerebral low-grade glioma,” Journal of Clinical Oncology, vol. 20, no. 8, pp. 2076–2084, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Pallud, P. Varlet, B. Devaux et al., “Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities,” Neurology, vol. 74, no. 21, pp. 1724–1731, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Pallud, L. Capelle, L. Taillandier et al., “Prognostic signifcance of imaging contrast enhancement for WHO grade II gliomas,” Neuro-Oncology, vol. 11, no. 2, pp. 176–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Mandonnet, J. Y. Delattre, M. L. Tanguy et al., “Continuous growth of mean tumor diameter in a subset of grade II gliomas,” Annals of Neurology, vol. 53, no. 4, pp. 524–528, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Pallud, E. Mandonnet, H. Duffau et al., “Prognostic value of initial magnetic resonance imaging growth rates for world health organization grade II gliomas,” Annals of Neurology, vol. 60, no. 3, pp. 380–383, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Rees, H. Watt, H. R. Jäger et al., “Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation,” European Journal of Radiology, vol. 72, no. 1, pp. 54–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. U. Roelcke and K. L. Leenders, “PET in neuro-oncology,” Journal of Cancer Research and Clinical Oncology, vol. 127, no. 1, pp. 2–8, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Herholz, U. Pietrzyk, J. Voges et al., “Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study,” Journal of Neurosurgery, vol. 79, no. 6, pp. 853–858, 1993. View at Google Scholar · View at Scopus
  29. S. Goldman, M. Levivier, B. Pirotte et al., “Regional glucose metabolism and histopathology of gliomas: a study based on positron emission tomography-guided stereotactic biopsy,” Cancer, vol. 78, no. 5, pp. 1098–1106, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Levivier, D. Wikler, N. Massager et al., “The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review,” Journal of Neurosurgery, vol. 97, no. 5, pp. 542–550, 2002. View at Google Scholar · View at Scopus
  31. P. L. Jager, W. Vaalburg, J. Pruim, E. G. E. De Vries, K. J. Langen, and D. A. Piers, “Radiolabeled amino acids: basic aspects and clinical applications in oncology,” Journal of Nuclear Medicine, vol. 42, no. 3, pp. 432–445, 2001. View at Google Scholar · View at Scopus
  32. M. Bergstrom, H. Lundqvist, K. Ericson et al., “Comparison of the accumulation kinetics of L-(methyl-C)-methionine and D-(methyl-C)-methionine in brain tumors studied with positron emission tomography,” Acta Radiologica, vol. 28, no. 3, pp. 225–229, 1987. View at Google Scholar · View at Scopus
  33. N. Sato, M. Suzuki, N. Kuwata et al., “Evaluation of the malignancy of glioma using C-methionine positron emission tomography and proliferating cell nuclear antigen staining,” Neurosurgical Review, vol. 22, no. 4, pp. 210–214, 1999. View at Google Scholar · View at Scopus
  34. L. W. Kracht, M. Friese, K. Herholz et al., “Methyl-[C]-L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 6, pp. 868–873, 2003. View at Google Scholar · View at Scopus
  35. Y. Okita, M. Kinoshita, T. Goto et al., “C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison,” NeuroImage, vol. 49, no. 4, pp. 2977–2982, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. J. M. Derlon, C. Bourdet, P. Bustany et al., “[11C]L-Methionine uptake in gliomas,” Neurosurgery, vol. 25, no. 5, pp. 720–728, 1989. View at Google Scholar · View at Scopus
  37. S. Goldman, M. Levivier, B. Pirotte et al., “Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy,” Journal of Nuclear Medicine, vol. 38, no. 9, pp. 1459–1462, 1997. View at Google Scholar · View at Scopus
  38. M. Sasaki, Y. Kuwabara, T. Yoshida et al., “A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours,” European Journal of Nuclear Medicine, vol. 25, no. 9, pp. 1261–1269, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. J. M. Derlon, F. Chapon, M. H. Noël et al., “Non-invasive grading of oligodendrogliomas: correlations between in vivo metabolic pattern and histopathology,” European Journal of Nuclear Medicine, vol. 27, no. 7, pp. 778–787, 2000. View at Google Scholar · View at Scopus
  40. B. Kaschten, A. Stevenaert, B. Sadzot et al., “Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine,” Journal of Nuclear Medicine, vol. 39, no. 5, pp. 778–785, 1998. View at Google Scholar · View at Scopus
  41. D. J. Coope, J. Čížek, C. Eggers, S. Vollmar, W. D. Heiss, and K. Herholz, “Evaluation of primary brain tumors using C-methionine PET with reference to a normal methionine uptake map,” Journal of Nuclear Medicine, vol. 48, no. 12, pp. 1971–1980, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Pauleit, G. Stoffels, A. Bachofner et al., “Comparison of F-FET and F-FDG PET in brain tumors,” Nuclear Medicine and Biology, vol. 36, no. 7, pp. 779–787, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. W. A. Weber, H. J. Wester, A. L. Grosu et al., “O-(2-[F]fluoroethyl)-L-tyrosine and L-[methyl-C]methionine uptake in brain tumours: initial results of a comparative study,” European Journal of Nuclear Medicine, vol. 27, no. 5, pp. 542–549, 2000. View at Google Scholar · View at Scopus
  44. K. J. Langen, M. Jarosch, H. Mühlensiepen et al., “Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas,” Nuclear Medicine and Biology, vol. 30, no. 5, pp. 501–508, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Pauleit, F. Floeth, K. Hamacher et al., “O-(2-[F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas,” Brain, vol. 128, no. 3, pp. 678–687, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Herholz and W. D. Heiss, “Positron emission tomography in clinical neurology,” Molecular Imaging and Biology, vol. 6, no. 4, pp. 239–269, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. W. D. Heiss, K. Wienhard, R. Wagner et al., “F-Dopa as an amino acid tracer to detect brain tumors,” Journal of Nuclear Medicine, vol. 37, no. 7, pp. 1180–1182, 1996. View at Google Scholar · View at Scopus
  48. W. Chen, D. H. S. Silverman, S. Delaloye et al., “F-FDOPA PET imaging of brain tumors: comparison study with F-FDG PET and evaluation of diagnostic accuracy,” Journal of Nuclear Medicine, vol. 47, no. 6, pp. 904–911, 2006. View at Google Scholar · View at Scopus
  49. M. Tripathi, R. Sharma, M. D'Souza et al., “Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas,” Clinical Nuclear Medicine, vol. 34, no. 12, pp. 878–883, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. B. J. Fueger, J. Czernin, T. Cloughesy et al., “Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas,” Journal of Nuclear Medicine, vol. 51, no. 10, pp. 1532–1538, 2010. View at Google Scholar
  51. H. Minn, “PET and SPECT in low-grade glioma,” European Journal of Radiology, vol. 56, no. 2, pp. 171–178, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Pöpperl, F. W. Kreth, J. H. Mehrkens et al., “FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 12, pp. 1933–1942, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Thiele, J. Ehmer, M. D. Piroth et al., “The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma,” Physics in Medicine and Biology, vol. 54, no. 18, pp. 5525–5539, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. B. N. T. Tang, N. Sadeghi, F. Branle, O. Witte, D. Wikler, and S. Goldman, “Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma,” Journal of Neuro-Oncology, vol. 71, no. 2, pp. 161–168, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. F. G. Dhermain, P. Hau, H. Lanfermann, A. H. Jacobs, and M. J. van den Bent, “Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas,” The Lancet Neurology, vol. 9, no. 9, pp. 906–920, 2010. View at Publisher · View at Google Scholar
  56. L. W. Kracht, H. Miletic, S. Busch et al., “Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology,” Clinical Cancer Research, vol. 10, no. 21, pp. 7163–7170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Sadeghi, I. Salmon, B. N. T. Tang et al., “Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results,” Journal of Magnetic Resonance Imaging, vol. 24, no. 5, pp. 989–994, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Sadeghi, I. Salmon, C. Decaestecker et al., “Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma,” American Journal of Neuroradiology, vol. 28, no. 3, pp. 455–461, 2007. View at Google Scholar · View at Scopus
  59. J. M. Derlon, M. C. Petit-Taboué, F. Chapon et al., “The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using F-fluorodeoxyglucose and C-L- methylmethionine,” Neurosurgery, vol. 40, no. 2, pp. 276–288, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Herholz, T. Hölzer, B. Bauer et al., “C-methionine PET for differential diagnosis of low-grade gliomas,” Neurology, vol. 50, no. 5, pp. 1316–1322, 1998. View at Google Scholar · View at Scopus
  61. N. Galldiks, L. W. Kracht, F. Berthold et al., “[C]-L-Methionine positron emission tomography in the management of children and young adults with brain tumors,” Journal of Neuro-Oncology, vol. 96, no. 2, pp. 231–239, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Pichler, A. Dunzinger, G. Wurm et al., “Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 8, pp. 1521–1528, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Nuutinen, P. Sonninen, P. Lehikoinen et al., “Radiotherapy treatment planning and long-term follow-up with [11C]methionine PET in patients with low-grade astrocytoma,” International Journal of Radiation Oncology Biology Physics, vol. 48, no. 1, pp. 43–52, 2000. View at Publisher · View at Google Scholar
  64. B. Pirotte, S. Goldman, P. David et al., “Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine,” Acta neurochirurgica. Supplement, vol. 68, pp. 133–138, 1997. View at Google Scholar · View at Scopus
  65. U. Roelcke, K. Von Ammon, O. Hausmann et al., “Operated low grade astrocytomas: a long term PET study on the effect of radiotherapy,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 5, pp. 644–647, 1999. View at Google Scholar · View at Scopus
  66. J. Voges, K. Herholz, T. Hölzer et al., “C-methionine andF-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy withI seeds,” Stereotactic and Functional Neurosurgery, vol. 69, no. 1–4, part 2, pp. 129–135, 1997. View at Google Scholar · View at Scopus
  67. M. Würker, K. Herholz, J. Voges et al., “Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy,” European Journal of Nuclear Medicine, vol. 23, no. 5, pp. 583–586, 1996. View at Google Scholar · View at Scopus
  68. T. Yamane, S. Sakamoto, and M. Senda, “Clinical impact of C-methionine PET on expected management of patients with brain neoplasm,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 4, pp. 685–690, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. N. Tsuyuguchi, I. Sunada, K. Ohata et al., “Evaluation of treatment effects in brain abscess with positron emission tomography: comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine,” Annals of Nuclear Medicine, vol. 17, no. 3, pp. 47–51, 2003. View at Google Scholar · View at Scopus
  70. B. Pirotte, S. Goldman, N. Massager et al., “Comparison of F-FDG and C-methionine for PET-guided stereotactic brain biopsy of gliomas,” Journal of Nuclear Medicine, vol. 45, no. 8, pp. 1293–1298, 2004. View at Google Scholar · View at Scopus
  71. D. C. Weber, T. Zilli, F. Buchegger et al., “[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma,” Radiation Oncology, vol. 3, no. 1, article 44, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Wyss, S. Hofer, M. Bruehlmeier et al., “Early metabolic responses in temozolomide treated low-grade glioma patients,” Journal of Neuro-Oncology, vol. 95, no. 1, pp. 87–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Van Laere, S. Ceyssens, F. Van Calenbergh et al., “Direct comparison of F-FDG and C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 1, pp. 39–51, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Terakawa, N. Tsuyuguchi, Y. Iwai et al., “Diagnostic accuracy of C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy,” Journal of Nuclear Medicine, vol. 49, no. 5, pp. 694–699, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. D. Ribom, M. Schoenmaekers, H. Engler, and A. Smits, “Evaluation of C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas,” Journal of Neuro-Oncology, vol. 71, no. 3, pp. 325–332, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. R. T. Ullrich, L. Kracht, A. Brunn et al., “Methyl-L-C-methionine PET as a diagnostic marker for malignant progression in patients with glioma,” Journal of Nuclear Medicine, vol. 50, no. 12, pp. 1962–1968, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. D. Ribom, A. Eriksson, M. Hartman et al., “Positron emission tomography C-methionine and survival in patients with low-grade gliomas,” Cancer, vol. 92, no. 6, pp. 1541–1549, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. O. De Witte, I. Goldberg, D. Wikler et al., “Positron emission tomography with injection of methionine as a prognostic factor in glioma,” Journal of Neurosurgery, vol. 95, no. 5, pp. 746–750, 2001. View at Google Scholar · View at Scopus
  79. F. W. Floeth, D. Pauleit, M. Sabel et al., “Prognostic value of O-(2-F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma,” Journal of Nuclear Medicine, vol. 48, no. 4, pp. 519–527, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Singhal, T. K. Narayanan, V. Jain, J. Mukherjee, and J. Mantil, “C-L-methionine positron emission tomography in the clinical management of cerebral gliomas,” Molecular Imaging and Biology, vol. 10, no. 1, pp. 1–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Henze, A. Mohammed, H. P. Schlemmer et al., “PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis,” Journal of Nuclear Medicine, vol. 45, no. 4, pp. 579–586, 2004. View at Google Scholar · View at Scopus
  82. O. Bělohlávek, J. Klener, J. Vymazal, V. Dbalý, and F. Tovaryš, “The diagnostics of recurrent gliomas using FDG-PET: still questionable?” Nuclear Medicine Review, vol. 5, no. 2, pp. 127–130, 2002. View at Google Scholar
  83. S. T. Chao, J. H. Suh, S. Raja, S. Y. Lee, and G. Barnett, “The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery,” International Journal of Cancer, vol. 96, no. 3, pp. 191–197, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Mineura, T. Sasajima, M. Kowada, T. Ogawa, J. Hatazawa, and K. Uemura, “Long-term positron emission tomography evaluation of slowly progressive gliomas,” European Journal of Cancer Part A, vol. 32, no. 7, pp. 1257–1260, 1996. View at Publisher · View at Google Scholar · View at Scopus
  85. F. W. Floeth, M. Sabel, G. Stoffels et al., “Prognostic value of F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions,” Journal of Nuclear Medicine, vol. 49, no. 5, pp. 730–737, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Ribom, H. Engler, E. Blomquist, and A. Smits, “Potential significance of 11C-methionine PET as a marker for the radiosensitivity of low-grade gliomas,” European Journal of Nuclear Medicine, vol. 29, no. 5, pp. 632–640, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. S. W. Coons, P. C. Johnson, and J. R. Shapiro, “Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma,” Cancer Research, vol. 55, no. 7, pp. 1569–1577, 1995. View at Google Scholar · View at Scopus
  88. S. Rudoler, B. W. Corn, M. Werner-Wasik et al., “Patterns of tumor progression after radiotherapy for low-grade gliomas: analysis from the computed tomography/magnetic resonance imaging era,” American Journal of Clinical Oncology, vol. 21, no. 1, pp. 23–27, 1998. View at Publisher · View at Google Scholar · View at Scopus
  89. M. T. Wyss, S. Hofer, M. Hefti et al., “Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake,” Journal of Nuclear Medicine, vol. 48, no. 7, pp. 1047–1052, 2007. View at Publisher · View at Google Scholar · View at Scopus